Latest Breaking News On - Sclerosis model - Page 1 : comparemela.com

Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.

Noord hollandNational harborUnited statesMerck kgaa darmstadtConsortium of multiple sclerosis centersMerck kgaaResearch in multiple sclerosis congressMerck kgaResearch developmentEuropean committee for treatmentSclerosis modelMultiple sclerosis centersMultiple sclerosis congressMultiple sclerosisPhase 3 trial